Which has stronger earnings & valuation, MNPR or ONCY?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is MNPR or ONCY more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Oncolytics Biotech N/A -2,185.97% -321.54%

Which has stronger earnings and valuation, ANL or ONCY?

Oncolytics Biotech has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 82.56 -$35.53M N/A N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is ANL or ONCY more profitable?

Adlai Nortye's return on equity of 0.00% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Oncolytics Biotech N/A -2,185.97% -321.54%

Which has higher earnings and valuation, EPRX or ONCY?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is EPRX or ONCY more profitable?

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Oncolytics Biotech N/A -2,185.97% -321.54%

Which has better earnings & valuation, IPSC or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Century Therapeutics N/A N/A -$9.58M -$1.14 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is IPSC or ONCY more profitable?

Century Therapeutics' return on equity of -49.89% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Oncolytics Biotech N/A -2,185.97% -321.54%

Oncolytics Biotech (ONCY) Competitors

$0.80 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.49%)

As of 06/12/2026 07:57 PM Eastern

Compare

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

Should you buy Oncolytics Biotech stock or one of its competitors? MarketBeat compares Oncolytics Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncolytics Biotech include Monopar Therapeutics (MNPR), Adlai Nortye (ANL), Eupraxia Pharmaceuticals (EPRX), Century Therapeutics (IPSC), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

How does Oncolytics Biotech compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

In the previous week, Monopar Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 2 mentions for Monopar Therapeutics and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Monopar Therapeutics' score of 0.41 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Monopar Therapeutics	Neutral
Oncolytics Biotech	Very Positive

Monopar Therapeutics' return on equity of -12.84% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Monopar Therapeutics currently has a consensus price target of $107.91, indicating a potential upside of 80.54%. Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 958.53%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Monopar Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 134.98%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 958.53%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Adlai Nortye and Adlai Nortye both had 1 articles in the media. Oncolytics Biotech's average media sentiment score of 1.89 beat Adlai Nortye's score of 1.87 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Very Positive
Oncolytics Biotech	Very Positive

Oncolytics Biotech has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	82.56	-$35.53M	N/A	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Adlai Nortye's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Adlai Nortye has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Oncolytics Biotech beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

6.8% of Oncolytics Biotech shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Eupraxia Pharmaceuticals' score of 0.62 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Positive
Oncolytics Biotech	Very Positive

Eupraxia Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, indicating a potential upside of 203.53%. Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 958.53%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Oncolytics Biotech beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	N/A	N/A	-$9.58M	-$1.14	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Century Therapeutics had 5 more articles in the media than Oncolytics Biotech. MarketBeat recorded 6 mentions for Century Therapeutics and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Century Therapeutics' score of 0.26 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Century Therapeutics	Neutral
Oncolytics Biotech	Very Positive

Century Therapeutics currently has a consensus price target of $4.75, suggesting a potential upside of 111.11%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 958.53%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Century Therapeutics' return on equity of -49.89% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Century Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Upstream Bio presently has a consensus target price of $33.17, suggesting a potential upside of 443.72%. Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 958.53%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

6.8% of Oncolytics Biotech shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oncolytics Biotech has lower revenue, but higher earnings than Upstream Bio. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	116.48	-$143.44M	-$2.91	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Upstream Bio has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, Upstream Bio had 9 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Upstream Bio and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Upstream Bio's score of 0.28 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Oncolytics Biotech	Very Positive

Oncolytics Biotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Summary

Upstream Bio and Oncolytics Biotech tied by winning 8 of the 16 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$95.84M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.59	20.00	24.00	24.42
Price / Sales	N/A	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-20.08	8.32	10.60	6.82
Net Income	-$28.76M	$23.94M	$3.57B	$337.56M
7 Day Performance	-4.40%	1.84%	0.59%	1.16%
1 Month Performance	-5.53%	-0.04%	1.54%	3.16%
1 Year Performance	32.07%	44.82%	25.41%	30.60%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	2.4321 of 5 stars	$0.80 flat	$8.50 +958.5%	+32.1%	$95.84M	N/A	N/A	30	Positive News Gap Up
MNPR Monopar Therapeutics	2.0244 of 5 stars	$60.61 +1.9%	$107.91 +78.0%	+78.3%	$398.46M	N/A	N/A	10	News Coverage Analyst Downgrade
ANL Adlai Nortye	2.1946 of 5 stars	$10.23 +2.8%	$24.25 +137.0%	+512.5%	$398M	$5M	N/A	127	Gap Up
EPRX Eupraxia Pharmaceuticals	2.2375 of 5 stars	$5.99 +0.7%	$18.33 +206.1%	+56.5%	$386.86M	N/A	N/A	29	News Coverage
IPSC Century Therapeutics	2.0994 of 5 stars	$2.12 -0.5%	$4.75 +124.1%	+291.0%	$384.16M	N/A	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

How does Oncolytics Biotech compare to Monopar Therapeutics?

Summary

How does Oncolytics Biotech compare to Adlai Nortye?

Summary

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

How does Oncolytics Biotech compare to Monopar Therapeutics?

Which has stronger earnings & valuation, MNPR or ONCY?

Which has more risk & volatility, MNPR or ONCY?

Does the media favor MNPR or ONCY?

Is MNPR or ONCY more profitable?

Do analysts recommend MNPR or ONCY?

Do insiders and institutionals believe in MNPR or ONCY?

Summary

How does Oncolytics Biotech compare to Adlai Nortye?

Do analysts rate ANL or ONCY?

Does the media favor ANL or ONCY?

Which has stronger earnings and valuation, ANL or ONCY?

Is ANL or ONCY more profitable?

Which has more risk & volatility, ANL or ONCY?

Do insiders & institutionals believe in ANL or ONCY?

Summary

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Do institutionals and insiders believe in EPRX or ONCY?

Which has higher earnings and valuation, EPRX or ONCY?

Does the media refer more to EPRX or ONCY?

Which has more volatility and risk, EPRX or ONCY?

Is EPRX or ONCY more profitable?

Do analysts prefer EPRX or ONCY?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Which has better earnings & valuation, IPSC or ONCY?

Does the media favor IPSC or ONCY?

Do analysts prefer IPSC or ONCY?

Is IPSC or ONCY more profitable?

Which has more risk & volatility, IPSC or ONCY?

Do insiders and institutionals have more ownership in IPSC or ONCY?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Do analysts prefer UPB or ONCY?

Do insiders & institutionals have more ownership in UPB or ONCY?

Which has higher valuation & earnings, UPB or ONCY?

Which has more volatility & risk, UPB or ONCY?

Does the media favor UPB or ONCY?

Is UPB or ONCY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools